Dec. 31 at 1:55 PM
The "abscopal effect"—where local radiation triggers the immune system to attack tumors throughout the entire body—is the holy grail of oncology. Here are the tickers leading the charge into 2026:
$DRTS (Alpha Tau Medical)
The pure play. Their Alpha DaRT technology isn't just killing local tumors; clinical data shows it triggers a systemic immune response. With pancreatic and skin cancer trials hitting major milestones, it’s the top pick for investors chasing the abscopal dream.
$NBTX (Nanobiotix)
Their lead candidate, NBTXR3, is designed to "radio-render" tumors more sensitive to radiation. Partnered with Janssen, they are proving that enhancing local radiotherapy can ignite the immune system to fight distant metastases.
$AZN (AstraZeneca)
The giant in the room. AZN is aggressively testing its checkpoint inhibitors (like Imfinzi) in combo with radiotherapy. They are betting that "priming" the body with immunotherapy will turn standard radiation into a systemic abscopal machine.
